Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Constellation Pharmaceuticals, Inc is a biotechnology business based in the US. Constellation Pharmaceuticals shares (CNST) are listed on the NASDAQ and all prices are listed in US Dollars. Constellation Pharmaceuticals employs 106 staff and has a market cap (total outstanding shares value) of USD$1.1 billion.
Since the stock market crash in March caused by coronavirus, Constellation Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$21.65, which is 42.42% down on its pre-crash value of USD$37.6 and 17.43% up on the lowest point reached during the March crash when the shares fell as low as USD$18.437.
If you had bought USD$1,000 worth of Constellation Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$867.05 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$648.42.
|Latest market close||USD$21.65|
|52-week range||USD$11.66 - USD$50.9|
|50-day moving average||USD$21.6574|
|200-day moving average||USD$29.538|
|Wall St. target price||USD$44.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.125|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||3.00%|
|1 month (2020-10-23)||-10.54%|
|3 months (2020-08-24)||-2.70%|
|6 months (2020-05-22)||-41.72%|
|1 year (2019-11-22)||-45.51%|
|2 years (2018-11-23)||261.44%|
|3 years (2017-11-20)||N/A|
|5 years (2015-11-20)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-19.39%|
|Return on equity TTM||-37.3%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 5.0 million Constellation Pharmaceuticals shares held short by investors – that's known as Constellation Pharmaceuticals's "short interest". This figure is 30.5% up from 3.8 million last month.
There are a few different ways that this level of interest in shorting Constellation Pharmaceuticals shares can be evaluated.
Constellation Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Constellation Pharmaceuticals shares currently shorted divided by the average quantity of Constellation Pharmaceuticals shares traded daily (recently around 563793.629124). Constellation Pharmaceuticals's SIR currently stands at 8.79. In other words for every 100,000 Constellation Pharmaceuticals shares traded daily on the market, roughly 8790 shares are currently held short.
However Constellation Pharmaceuticals's short interest can also be evaluated against the total number of Constellation Pharmaceuticals shares, or, against the total number of tradable Constellation Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Constellation Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Constellation Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1527% of the tradable shares (for every 100,000 tradable Constellation Pharmaceuticals shares, roughly 153 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Constellation Pharmaceuticals.
Find out more about how you can short Constellation Pharmaceuticals stock.
We're not expecting Constellation Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Constellation Pharmaceuticals's shares have ranged in value from as little as $11.66 up to $50.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Constellation Pharmaceuticals's is 2.896. This would suggest that Constellation Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Steps to owning and managing CBAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHAP, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRS, with 24-hour and historical pricing before you buy.
Steps to owning and managing AXLA, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMPE, with 24-hour and historical pricing before you buy.
Steps to owning and managing UHAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALIM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.